Journal of vascular surgery · 2014
Duplex ultrasound diagnosis of failing stent grafts placed for occlusive disease.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Troutman Douglas A, Madden Nicholas J, Dougherty Matthew J, Calligaro Keith D
Аннотация
OBJECTIVE: We previously showed that duplex ultrasound (DU) imaging is beneficial in the diagnosis of failing vein and prosthetic grafts performed for arterial occlusive disease. The purpose of this study was to evaluate whether DU imaging can reliably diagnose failing stent grafts (ie, covered stents) placed for arterial occlusive disease.
METHODS: Between July 1, 2005, and June 30, 2013, we placed 142 stent grafts in 92 arterial segments (1.5 stent grafts/stenotic artery) for lower extremity occlusive disease in patients who also underwent at least one DU surveillance study documenting a patent stent graft. Stent grafts were placed in 29 iliac and 52 femoropopliteal arteries and in 11 failing infrainguinal bypass grafts. Stent grafts used were Viabahn (W. L. Gore and Associates Inc, Flagstaff, Ariz) in 116 (82%), Wallgraft (Boston Scientific, Natick, Mass) in 23 (16%), Fluency (C. R. Bard Inc, Tempe, Ariz) in 2 (1%), and iCast (Atrium, Hudson, NH) in 1 (1%). Mean follow-up was 16 months (range, 1 week-86 months). Postoperative DU surveillance was performed in our Intersocietal Accreditation Commission accredited noninvasive vascular laboratory at 1 week, then every 3 months the first year, and every 6 months thereafter. DU measured peak systolic velocities (PSVs) and velocity ratio of adjacent PSVs (Vr) every 5 cm within the stent graft and adjacent arteries.
RESULTS: We retrospectively classified the following factors as "abnormal DU findings:" focal PSVs >300 cm/s, uniform PSVs <50 cm/s throughout the graft, and a Vr >3.0. Fifteen of 20 patients with one or more of these abnormal DU findings underwent prophylactic intervention (n = 8) or occluded without intervention (n = 7), whereas only two of 72 with normal DU findings occluded (P = .0001). Excluding the eight patients who underwent prophylactic intervention, seven of 12 patients with abnormal DU findings occluded without intervention vs two of 72 with normal DU findings (P = .0001).
CONCLUSIONS: These findings suggest that follow-up DU surveillance can predict failure of stent grafts placed for lower extremity occlusive disease. Focal PSVs >300 cm/s, Vr >3.0, and most importantly, uniform PSVs <50 cm/s throughout the stent graft were statistically reliable markers for predicting stent graft thrombosis.
METHODS: Between July 1, 2005, and June 30, 2013, we placed 142 stent grafts in 92 arterial segments (1.5 stent grafts/stenotic artery) for lower extremity occlusive disease in patients who also underwent at least one DU surveillance study documenting a patent stent graft. Stent grafts were placed in 29 iliac and 52 femoropopliteal arteries and in 11 failing infrainguinal bypass grafts. Stent grafts used were Viabahn (W. L. Gore and Associates Inc, Flagstaff, Ariz) in 116 (82%), Wallgraft (Boston Scientific, Natick, Mass) in 23 (16%), Fluency (C. R. Bard Inc, Tempe, Ariz) in 2 (1%), and iCast (Atrium, Hudson, NH) in 1 (1%). Mean follow-up was 16 months (range, 1 week-86 months). Postoperative DU surveillance was performed in our Intersocietal Accreditation Commission accredited noninvasive vascular laboratory at 1 week, then every 3 months the first year, and every 6 months thereafter. DU measured peak systolic velocities (PSVs) and velocity ratio of adjacent PSVs (Vr) every 5 cm within the stent graft and adjacent arteries.
RESULTS: We retrospectively classified the following factors as "abnormal DU findings:" focal PSVs >300 cm/s, uniform PSVs <50 cm/s throughout the graft, and a Vr >3.0. Fifteen of 20 patients with one or more of these abnormal DU findings underwent prophylactic intervention (n = 8) or occluded without intervention (n = 7), whereas only two of 72 with normal DU findings occluded (P = .0001). Excluding the eight patients who underwent prophylactic intervention, seven of 12 patients with abnormal DU findings occluded without intervention vs two of 72 with normal DU findings (P = .0001).
CONCLUSIONS: These findings suggest that follow-up DU surveillance can predict failure of stent grafts placed for lower extremity occlusive disease. Focal PSVs >300 cm/s, Vr >3.0, and most importantly, uniform PSVs <50 cm/s throughout the stent graft were statistically reliable markers for predicting stent graft thrombosis.
Предметные рубрики MeSH
Arterial Occlusive DiseasesBlood Flow VelocityBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationEndovascular ProceduresGraft Occlusion, VascularHumansLower ExtremityPredictive Value of TestsProsthesis DesignProsthesis FailureRegional Blood FlowReproducibility of ResultsRetrospective StudiesRisk FactorsStentsThrombosisTime FactorsTreatment OutcomeUltrasonography, Doppler, DuplexVascular Patency